Scientists Testing Controversial Human Rejuvenation Compound Called ER-100

"For many years now, youth-obsessed billionaires have been forking out immense sums to try experimental techniques that could turn back the clock on their aging bodies. Meanwhile, a cottage industry of anti-aging companies claiming to have the answer has cropped up, racing to test their treatments on humans. Case in point, Harvard professor David Sinclair, who has previously been accused of having little to show to investors after raising more than $1 billion for his anti-aging businesses, boasted in response to Musk on X that "aging has a relatively simple explanation and is apparently reversible," cryptically hinting at "clinical trials" that will "begin shortly.""

"As MIT Technology Review reports, Sinclair's Boston-based startup, Life Biosciences, is working on a treatment code-named ER-100. The company announced on Tuesday that its planned clinical trials had been greenlit by the US Food and Drug Administration. As part of its trial, Life Biosciences is looking to treat glaucoma, a group of eye diseases caused by pressure in the eye that often results in irreversible damage to the optic nerve, by "resetting" human participants' cells, effectively "reprogramming" them to a healthier state. A single dose of viruses that include gene-reprogramming instructions will be injected into one eye of each participant. A special genetic switch will be used to control how far the treatment goes. The tech relies on research by Japanese stem cell researcher and Nobel Prize laureate Shinya Yamanaka, who discovered in the early 2000s that special genes - later dubbed Yamanaka factors - can be used to transfo"

Deep-pocketed investors and private biotech firms are funding experimental anti-aging approaches and a growing number of companies pursue human tests. A startup named Life Biosciences received FDA clearance to begin planned clinical trials of ER-100, a therapy aimed at treating glaucoma by resetting and reprogramming cells to a healthier state. The protocol delivers a single dose of viruses containing gene-reprogramming instructions into one eye, with a genetic switch to control the extent of reprogramming. The approach builds on Yamanaka-factor research that demonstrated certain genes can revert cells toward a more youthful state. Some researchers have faced criticism over fundraising versus demonstrable results.

Read at Futurism